Brain injury · 2005
Botulinum toxin type A in the treatment of children and adolescents with an acquired brain injury.
СтатьяРандомизированное исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
van Rhijn J, Molenaers G, Ceulemans B
Аннотация
PRIMARY OBJECTIVE: To describe clinical experience using botulinum toxin type A (BTX-A) in children with acquired brain injury.
RESEARCH DESIGN: Single centre, open label, pilot study.
METHODS AND PROCEDURES: Twenty-one patients were randomized to three groups according to impairment severity and treatment objectives.
EXPERIMENTAL INTERVENTIONS: Group 1: Spastic quadriparesis patients with impaired consciousness treated with the primary goal of improving comfort and well-being; Group 2: Patients with upper limb spasticity treated with the primary goal of improving arm functioning; Group 3: Lower limb spasticity patients treated with the primary goal of improving leg function.
OUTCOMES AND RESULTS: Baseline, 1, 3 and 5-month post-treatment assessments were carried out using joint goniometry, Modified Ashworth Scale and video-observations. All groups demonstrated initial improvements, with patients in Group 2 showing a positive effect at least 5 months post-treatment.
CONCLUSIONS: With a good outlining of treatment goals, BTX-A is an effective therapy for brain injury patients.
RESEARCH DESIGN: Single centre, open label, pilot study.
METHODS AND PROCEDURES: Twenty-one patients were randomized to three groups according to impairment severity and treatment objectives.
EXPERIMENTAL INTERVENTIONS: Group 1: Spastic quadriparesis patients with impaired consciousness treated with the primary goal of improving comfort and well-being; Group 2: Patients with upper limb spasticity treated with the primary goal of improving arm functioning; Group 3: Lower limb spasticity patients treated with the primary goal of improving leg function.
OUTCOMES AND RESULTS: Baseline, 1, 3 and 5-month post-treatment assessments were carried out using joint goniometry, Modified Ashworth Scale and video-observations. All groups demonstrated initial improvements, with patients in Group 2 showing a positive effect at least 5 months post-treatment.
CONCLUSIONS: With a good outlining of treatment goals, BTX-A is an effective therapy for brain injury patients.